Lv2
130 积分 2022-12-09 加入
From target discovery to clinical drug development with human genetics
8小时前
待确认
Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors
1个月前
已关闭
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2个月前
已完结
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
3个月前
已完结
PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets
3个月前
已完结
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
7个月前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
7个月前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
9个月前
已完结
SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models
9个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
11个月前
已完结
皖公网安备34019202002308
